We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-5.50 | -4.03% | 131.00 | 127.00 | 135.00 | 131.00 | 124.00 | 124.00 | 45,106 | 08:03:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 3.54M | -9.26M | -0.3024 | -4.33 | 40.12M |
TIDMAREC
RNS Number : 4316Y
Arecor Therapeutics PLC
03 January 2024
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR APPOINTS DR HELEN PARRIS AS SENIOR VICE PRESIDENT, COMMERCIAL AND GENERAL MANAGER OF TETRIS PHARMA LTD
Cambridge, UK, 3 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, is pleased to announce the appointment of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of the Group's subsidiary company, Tetris Pharma Ltd ("Tetris Pharma"), effective Monday 15 January 2024.
Helen has over 20 years of scientific, commercial and government affairs experience across several international biopharmaceutical companies and has been responsible for launching transformational products and shaping markets across large pharmaceutical and biotechnology companies. Prior to joining Tetris Pharma, Helen served as General Manager Northern Markets (UK, Netherlands and Nordics) at Albireo Pharma, Inc., which was acquired by Ipsen (Euronext: IPN; ADR: IPSEY) in March 2023, and where she played a key role in establishing and building the regional affiliate and launching the first product to market.
Previously, Helen held multiple positions at Gilead (NASDAQ: GILD), including Executive Director EMEA, Global Affairs Regional Lead, and was instrumental in broadening patient access to treatment. Whilst at Gilead, Helen led the launch of several transformational drugs, developed critical launch strategies and expanded commercial opportunities.
Helen holds a BSc in Biology from York University, a PhD from Leeds University and an MBA from Henley Management College.
Sarah Howell, Chief Executive Officer at Arecor, said: "I am delighted to welcome Helen to Tetris Pharma and the Arecor Group as a key member of our leadership team. Helen's proven track record in bringing products to market and growing sales will be key as we continue the roll-out of Ogluo(R) across the UK and Europe. Ogluo (R) is an important treatment for people with diabetes and their caregivers that can provide them with the confidence to manage severe hypoglycaemic events and, under Helen's leadership, Tetris Pharma is even better positioned for the continued adoption of this key product in a c.GBP100 million market. Not only will this deliver a revenue stream but a successful commercial distribution platform through Tetris Pharma is highly complementary to our existing specialty hospital products business and has significant growth potential, providing Arecor with the capability to take selected products to market in the UK and Europe."
Dr. Helen Parris, S enior Vice President, Commercial and General Manager at Tetris Pharma, commented: "I am thrilled to be joining the team at Tetris Pharma to support the development of the company's lead product, Ogluo (R), and continue its accelerated roll-out across Europe. Ogluo(R) meets a key need for people living with diabetes at risk of severe hypoglycaemia, a condition which can have a profound effect on the everyday lives of those with diabetes and their caregivers. I look forward to leading the company as it continues to expand its pan-European presence."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060 Officer Email: info@arecor.com Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com Mo Noonan, Communications Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500 and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) ICR Consilium Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700 Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCEAXFAEALLEFA
(END) Dow Jones Newswires
January 03, 2024 02:00 ET (07:00 GMT)
1 Year Arecor Therapeutics Chart |
1 Month Arecor Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions